What was the overall market valuation for the UK polycystic ovarian-syndrome market in 2024?

The overall market valuation was $142.5 Million in 2024. Read More

What is the projected market valuation for the UK polycystic ovarian-syndrome market by 2035?

The projected valuation for 2035 is $210.25 Million. Read More

What is the expected CAGR for the UK polycystic ovarian-syndrome market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 3.6%. Read More

Which key players are leading the UK polycystic ovarian-syndrome market?

Key players include Bristol-Myers Squibb, Merck & Co., Bayer AG, AbbVie Inc., Novartis AG, Pfizer Inc., Sanofi, and Amgen Inc. Read More

What were the revenue figures for diagnostic methods in the UK polycystic ovarian-syndrome market?

In 2024, revenue from diagnostic methods included $30.0 Million from pelvic examinations, $50.0 Million from ultrasounds, and $62.5 Million from blood tests. Read More

What is the revenue range for treatment options in the UK polycystic ovarian-syndrome market?

Treatment options generated revenue ranging from $10.0 Million for anti-obesity treatments to $75.25 Million for surgery in 2024. Read More

What were the revenue figures for end-users in the UK polycystic ovarian-syndrome market?

In 2024, hospitals and clinics accounted for $85.5 Million, while ambulatory surgical centers contributed $57.0 Million. Read More

How does the market for oral contraceptives compare to other treatment options in 2024?

In 2024, oral contraceptives generated $30.0 Million, which is higher than antiandrogens and insulin sensitizing agents. Read More

What is the significance of the projected growth in the UK polycystic ovarian-syndrome market?

The projected growth indicates a rising awareness and demand for effective treatments, with the market expected to reach $210.25 Million by 2035. Read More

How do the revenues from blood tests compare to those from ultrasound diagnostics?

In 2024, blood tests generated $62.5 Million, surpassing ultrasound diagnostics, which accounted for $50.0 Million. Read More

UK Polycystic Ovarian Syndrome Market

ID: MRFR/HC/55068-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

UK Polycystic Ovarian Syndrome Market Research Report By Diagnosis (Pelvic Examination, Ultrasound, Blood Tests) - Growth & Industry Forecast 2025 To 2035

UK Polycystic Ovarian Syndrome Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Diagnosis (USD Million)
  1. 4.1.1 Pelvic examination
  2. 4.1.2 Ultrasound
  3. 4.1.3 Blood tests
2. 4.2 Construction, BY Treatment (USD Million)
  1. 4.2.1 Oral Contraceptives
  2. 4.2.2 Antiandrogens
  3. 4.2.3 Insulin Sensitizing Agent
  4. 4.2.4 Antidepressant
  5. 4.2.5 Anti-Obesity
  6. 4.2.6 Surgery
3. 4.3 Construction, BY End-user (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Ambulatory Surgical Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bayer AG (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AbbVie Inc. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 UK MARKET ANALYSIS BY TREATMENT
4. 6.4 UK MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CONSTRUCTION
8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
11. 6.11 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
12. 6.12 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
13. 6.13 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
14. 6.14 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 CONSTRUCTION, BY END-USER, 2024 (% SHARE)
16. 6.16 CONSTRUCTION, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Construction Market Segmentation

Construction By Diagnosis (USD Million, 2025-2035)

Pelvic examination
Ultrasound
Blood tests

Construction By Treatment (USD Million, 2025-2035)

Oral Contraceptives
Antiandrogens
Insulin Sensitizing Agent
Antidepressant
Anti-Obesity
Surgery

Construction By End-user (USD Million, 2025-2035)

Hospitals & Clinics
Ambulatory Surgical Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”